Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1721

Sort by

Sort Order Select

Journal Articles

Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and -independent effects by CDK6-specific PROTACs

Marco De Dominici, Patrizia Porazzi, Youcai Xiao, Allen Chao, Hsin-Yao Tang, Gaurav Kumar, Paolo Fortina, Orietta Spinelli, Alessandro Rambaldi, Luke F. Peterson, Svetlana Petruk, Camilla Barletta, Alexander Mazo, Gino Cingolani, Joseph M. Salvino, Bruno Calabretta

Blood (2020) 135 (18): 1560–1573.

https://doi.org/10.1182/blood.2019003604

Published: 2020

Includes: Supplemental data

Journal Articles

Integrated Transcriptomic and Genomic Sequencing Identifies Prognostic Constellations of Driver Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Ilaria Iacobucci, PhD, Manja Meggendorfer, PhD, Niroshan Nadarajah, Stanley Pounds, PhD, Lei Shi, PhD, Chunxu Qu, PhD, Constance Baer, PhD, Claudia Haferlach, MD, Wolfgang Kern, MD, Charles G. Mullighan, MBBS, MD, Torsten Haferlach, MD

Blood (2019) 134 (Supplement_2): LBA-4.

https://doi.org/10.1182/blood-2019-132746

Published: 2019

Journal Articles

Reducing the Burden of Chemoradiotherapy with the Combination of Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma

Jessica C. Hochberg, MD, Jaclyn Basso, RN, MSN, PNP, Liana Klejmont, Pharm D, Lauren Harrison, RN, MSN, Allyson M. Flower, MD, Aliza Gardenswartz, MD, Qiuhu Shi, PhD, Perry Gerard, MD MBA, FACR, Humayan Islam, MD, Mitchell S Cairo, MD

Blood (2019) 134 (Supplement_1): 127.

https://doi.org/10.1182/blood-2019-128684

Published: 2019

Journal Articles

Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia

Blood (2019) 134 (Supplement_1): 564.

https://doi.org/10.1182/blood-2019-129189

Published: 2019

Journal Articles

Mechanistic Basis and Efficacy of Targeting β-Catenin-TCF7L2-JMJD6-MYC Axis to Overcome Resistance to BET Inhibitors

Christopher Peter Mill, PhD BA, Warren Fiskus, BSc,PhD, Dyana T. Saenz, PhD, Bernardo H Lara, Vrajesh Karkhanis, PhD, Taghi Manshouri, PhD, Isean Bhalla, Nancy Shao, James V Maher, Srdan Verstovsek, MD PhD, Kapil N. Bhalla, MD

Blood (2019) 134 (Supplement_1): 538.

https://doi.org/10.1182/blood-2019-125142

Published: 2019

Journal Articles

Spatial Mapping of Myelopoiesis Reveals the Bone Marrow Niche for Monocyte Dendritic Cell Progenitors

Jizhou Zhang, Qingqing Wu, PhD, Courtney Johnson, BS, André Olsson, MS, PhD, Anastasiya Slaughter, BA, Margot Lindsay May, BS, Benjamin Weinhaus, BS, Emily Bowers, PhD, James Douglas Engel, PhD, Jean X. Jiang, PhD, Sherry L. Abboud-Werner, PhD, Nathan Salomonis, PhD, H. Leighton Grimes, PhD, Daniel Lucas-Alcaraz, PhD

Blood (2019) 134 (Supplement_1): 528.

https://doi.org/10.1182/blood-2019-128809

Published: 2019

Journal Articles

Mitochondrial Complex II in Intestinal Epithelial Cells Is a Critical Metabolic Checkpoint That Regulates Severity of Gastrointestinal Graft-Versus-Host Disease

Hideaki Fujiwara, Anna V Mathew, Ilya Kovalenko, Pal Anupama, Dan Peltier, Stephanie Kim, Austin Taylor, BA, Katherine Oravecz-Wilson, Yaping Sun, Costas Lyssiotis, Alnawaz Rehemtulla, Subramanian Pennarthur, Pavan Reddy

Blood (2019) 134 (Supplement_1): 584.

https://doi.org/10.1182/blood-2019-126775

Published: 2019

Journal Articles

Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins

Blood (2019) 134 (Supplement_1): 318.

https://doi.org/10.1182/blood-2019-130549

Published: 2019

Journal Articles

Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival after Repeat Infusions of CD19 CAR-T Cells

Evandro D. Bezerra, MD, Jordan Gauthier, MD MSc, Alexandre V. Hirayama, MD, Barbara S. Pender, MSc, Reed M. Hawkins, BS, Aesha Vakil, MSc, Rachel N. Steinmetz, BS, Aude G. Chapuis, MD, Brian G. Till, MD, Hans-Peter Kiem, MD PhD, Mazyar Shadman, MD MPH, Ryan D. Cassaday, MD, Stanley R. Riddell, MD, David G. Maloney, MD PhD, Cameron J. Turtle, MBBS, PhD

Blood (2019) 134 (Supplement_1): 201.

https://doi.org/10.1182/blood-2019-123807

Published: 2019

Journal Articles

The Impact and Modulation of Microenvironment-Induced Immune Resistance Against CAR T Cell and Antibody Treatments in Multiple Myeloma

Lisa C. Holthof, MSc, Hilma J. Van Der Horst, MSc, Renée Poels, Jort T. van der Schans, MSc, Anne T. Gelderloos, MSc, Fengzhi Li, Henk Lokhorst, MD PhD, Sonja Zweegman, MD PhD, Maria Themeli, MD PhD, Niels W. C. J. Van De Donk, Richard W.J. Groen, PhD, Tuna Mutis, MD PhD

Blood (2019) 134 (Supplement_1): 137.

https://doi.org/10.1182/blood-2019-125818

Published: 2019

Journal Articles

Highly Potent BTK Degradation Induced By NRX0492 As a Therapeutic Strategy for CLL

Deyi Zhang, PhD, Hailey Harris, Aileen Kelly, PhD, Daniel W Robbins, May Tan, Timothy Ingallinera, Neil Bence, Arthur T Sands, Sivasubramanian Baskar, Sarah E. M. Herman, Adrian Wiestner, MD PhD

Blood (2019) 134 (Supplement_1): 174.

https://doi.org/10.1182/blood-2019-126921

Published: 2019

Journal Articles

Hypersialylation Protects Multiple Myeloma Cells from NK Cell-Mediated Immunosurveillance and This Can be Overcome By Targeted Desialylation Using a Sialyltransferase Inhibitor

John Daly, MSc, Subhashis Sarkar, PhD, Alessandro Natoni, PhD, Robert Henderson, MB BCh, Dawn Swan, Mattias Carlsten, MD PhD, Michael E O'Dwyer, MD

Blood (2019) 134 (Supplement_1): 138.

https://doi.org/10.1182/blood-2019-126613

Published: 2019

Journal Articles

A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Paul M. Barr, MD, Brian T. Hill, MD, Shuo Ma, MD PhD, Andrea M Baran, MS, Andrew Bui, Philip J Meacham, MS, Ashley Morrison, Jane L. Liesveld, MD, Deborah A Mulford, MD, Peter Sportelli, BS, Hari P Miskin, MSc, Michael S Weiss, Jonathan W. Friedberg, MD, Clive S Zent, MD

Blood (2019) 134 (Supplement_1): 360.

https://doi.org/10.1182/blood-2019-123404

Published: 2019

Journal Articles

The Path to Cure: Using Haploidentical (haplo) Donors and High-Dose Post-Transplant Cyclophosphamide (PTCy) for Treatment-Naïve and Refractory Severe Aplastic Anemia (SAA)

Amy E. DeZern, MD, Marianna Zahurak, MS, Kenneth R. Cooke, MD, David Margolis, MD, Richard J. Jones, MD, Robert A. Brodsky, MD

Blood (2019) 134 (Supplement_1): 147.

https://doi.org/10.1182/blood-2019-121900

Published: 2019

Journal Articles

DT2216, a BCL-XL Proteolysis Targeting Chimera (PROTAC), Is a Potent Anti T-Cell Lymphoma Agent That Does Not Induce Significant Thrombocytopenia

Yonghan He, MD, Raphael Koch, Vivekananda Budamagunta, Dongwen Lv, Sajid Khan, Xuan Zhang, Janet S Wiegand, Guangrong Zheng, David M. Weinstock, MD, Daohong Zhou

Blood (2019) 134 (Supplement_1): 303.

https://doi.org/10.1182/blood-2019-125820

Published: 2019

Journal Articles

Allogeneic Chimeric Antigen Receptor-Invariant Natural Killer T Cells Exert Both Direct and Indirect Antitumor Effects through Host CD8 T Cell Cross-Priming

Federico Simonetta, MD PhD, Toshihito Hirai, MD PhD, Juliane K. Lohmeyer, MD, Kristina Maas-Bauer, MD, Maite Alvarez, PhD, Arielle S. Wenokur, Jeanette Baker, Amin Aalipour, PhD, Samuel Haile, PhD, Crystal L. Mackall, MD, Robert S. Negrin, MD

Blood (2019) 134 (Supplement_1): 867.

https://doi.org/10.1182/blood-2019-122515

Published: 2019

Journal Articles

Lncrnas As New Partners of Novel Chimeric Transcripts in Multiple Myeloma

Ane Amundarain, Luis Vitores Valcárcel, MSc, Raquel Ordoñez, PhD, Leire Garate, Estíbaliz Miranda, Xabier Cendoya, Maria Jose Calasanz, PhD BSc, Bruno Paiva, PhD, Jesús San-Miguel, Francisco J Planes, Felipe Prósper, MD PhD, Xabier Agirre, PhD

Blood (2019) 134 (Supplement_1): 4356.

https://doi.org/10.1182/blood-2019-122568

Published: 2019

Journal Articles

Combined Targeting of Distinct c-Myc and JunB Transcriptional Programs for Multiple Myelioma Therapy

Judith Lind, PhD, Felix Czernilofsky, Sonia Vallet, MD, Fengjuan Fan, PhD, Martin Sattler, PhD, Latifa Bakiri, Erwin F Wagner, PhD, Martin Percherstorfer, MD, Klaus Podar, MD PhD

Blood (2019) 134 (Supplement_1): 4415.

https://doi.org/10.1182/blood-2019-125202

Published: 2019

Journal Articles

Oncostatin M Is a Novel Niche Factor That Restrains Hematopoietic Stem Cell Mobilization in Response to G-CSF and CXCR4 Antagonist Plerixafor

Kavita Bisht, PhD, Crystal McGirr, Kylie A Alexander, Whitney Fleming, Natalie Sims, Gerhard Müller- Newen, Ingrid G Winkler, PhD, Jean-Pierre Levesque, PhD

Blood (2019) 134 (Supplement_1): 4469.

https://doi.org/10.1182/blood-2019-127431

Published: 2019

Journal Articles

Non-Hematopoietic Lymphoid Stromal Cells Prime Alloreactive CD4 + T Cells in Acute Graft-Versus-Host Disease

Muhammad Shaikh, MSc, Maria Ulbrich, MSc, Juan Gamboa Vargas, BSc, Katja J Ottmüller, PhD, Duc Dung Le, PhD, Zeinab Mokthari, PhD, Joern Pezoldt, PhD, Hermann Einsele, MD, Burkhard Ludewig, PhD, Jochen Huehn, PhD, Andreas Beilhack, MD

Blood (2019) 134 (Supplement_1): 4421.

https://doi.org/10.1182/blood-2019-125665

Published: 2019

NARROW

Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and -independent effects by CDK6-specific PROTACs

Integrated Transcriptomic and Genomic Sequencing Identifies Prognostic Constellations of Driver Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Reducing the Burden of Chemoradiotherapy with the Combination of Brentuximab Vedotin and Rituximab with Reduced Toxicity Chemotherapy in Children, Adolescents and Young Adults with Newly Diagnosed Hodgkin Lymphoma

Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia

Mechanistic Basis and Efficacy of Targeting β-Catenin-TCF7L2-JMJD6-MYC Axis to Overcome Resistance to BET Inhibitors

Spatial Mapping of Myelopoiesis Reveals the Bone Marrow Niche for Monocyte Dendritic Cell Progenitors

Mitochondrial Complex II in Intestinal Epithelial Cells Is a Critical Metabolic Checkpoint That Regulates Severity of Gastrointestinal Graft-Versus-Host Disease

Functional Characterization of E3 Ligases and Their Regulators: Therapeutic Implications for Development of New Proteolysis-Targeting Chimeric Degraders of Oncoproteins

Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival after Repeat Infusions of CD19 CAR-T Cells

The Impact and Modulation of Microenvironment-Induced Immune Resistance Against CAR T Cell and Antibody Treatments in Multiple Myeloma

Highly Potent BTK Degradation Induced By NRX0492 As a Therapeutic Strategy for CLL

Hypersialylation Protects Multiple Myeloma Cells from NK Cell-Mediated Immunosurveillance and This Can be Overcome By Targeted Desialylation Using a Sialyltransferase Inhibitor

A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

The Path to Cure: Using Haploidentical (haplo) Donors and High-Dose Post-Transplant Cyclophosphamide (PTCy) for Treatment-Naïve and Refractory Severe Aplastic Anemia (SAA)

DT2216, a BCL-XL Proteolysis Targeting Chimera (PROTAC), Is a Potent Anti T-Cell Lymphoma Agent That Does Not Induce Significant Thrombocytopenia

Allogeneic Chimeric Antigen Receptor-Invariant Natural Killer T Cells Exert Both Direct and Indirect Antitumor Effects through Host CD8 T Cell Cross-Priming

Lncrnas As New Partners of Novel Chimeric Transcripts in Multiple Myeloma

Combined Targeting of Distinct c-Myc and JunB Transcriptional Programs for Multiple Myelioma Therapy

Oncostatin M Is a Novel Niche Factor That Restrains Hematopoietic Stem Cell Mobilization in Response to G-CSF and CXCR4 Antagonist Plerixafor

Non-Hematopoietic Lymphoid Stromal Cells Prime Alloreactive CD4 + T Cells in Acute Graft-Versus-Host Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only